Connect with us

health and wellness

John Legend Announces Loved01 – Affordable Skincare for Melanin-Rich Skin

Published

on


Dermatologist-approved line of face and body products formulated for melanin-rich skin available at mass retail.

LOS ANGELES /PRNewswire/ — Today, award-winning singer-songwriter, entrepreneur and activist John Legend announces the launch of Loved01, a unisex skincare brand formulated in partnership with dermatologist Dr. Naana Boakye to treat the needs of melanin-rich skin. With accessibility at its core, the brand’s mission is to democratize skincare with affordably-priced products available at mass retail.

“Our mission is to celebrate melanin-rich skin and provide the love, care, and attention it deserves,” says Loved01 founder John Legend. “We hope to help democratize the beauty space by offering high-quality products at an accessible price point. Everyone deserves to be seen, represented and provided with the tools to love themselves, starting with healthy skin.”

At launch, Loved01 introduces six dermatologist-approved products to offer effective and nurturing skin-care for complexions of color, while addressing issues universal to all skin-types. The formulations are specifically balanced to moisturize, nourish, and uplift melanin-rich skin with natural ingredients that have a history in communities of color including Shea Butter, Jojoba and Coconut Oils and enhanced with the antioxidant properties of Rosehip Oil and Sea Buckthorn Oil. The line includes a Face + Body Wash, an Exfoliating Cleanser, a Shave Cream, a Toning Mist, a Face + Body Moisturizer, and a Face + Body Oil.

Founder of Loved01, John Legend, is dedicated to increasing inclusivity and representation in the skincare industry, and has teamed up with Dr. Boakye to help ensure formulations are of the highest efficacy and standard. Loved01 has worked to ensure all products are reviewed in-depth, bringing forth only the best ingredients and solutions for melanin-rich skin needs coming from a diverse and passionate group. 

Legend worked with A-Frame, a Los Angeles based holding company that develops talent-led sustainable personal care brands built for underserved communities, to make the Loved01 brand a reality. “John’s passion for highlighting a missing gap in the skin care space brought us together to make it possible for all to enjoy effective skincare solutions,” says President of Loved01, Kia Lowe. “We’re grateful to our loyal retail partners who have been so supportive and excited to help us reach our mission of making Loved01 accessible to all.”

Loved01 ensures skincare with effective ingredients for melanin-rich skin is financially accessible so that everyone has a chance to properly maintain the health and beauty of their own skin. Products will range in price between $10 – $15 and be available starting February 1st, 2023 on Loved01.com and at CVS Pharmacy locations nationwide and on CVS.com and launch in select Walmart stores and on Walmart.com in March 2023. For more information, visit loved01.com and follow @Loved01Skin on social.

Advertisement

ABOUT LOVED01
Founded by John Legend in February 2023, Loved01 is a personal care brand on a mission to democratize skincare by providing elevated, unisex skin and body products for melanin-rich skin, at an affordable price point. Featuring a line of 6 products at launch, Loved01 offers targeted skin-care solutions made of thoughtful ingredients for melanin-rich skin to deliver truly effective results. Loved01’s dermatologist-approved products nourish, moisturize and gently rebalance the skin’s pH levels, leaving users feeling clean, vibrant and beautiful. Rooted in accessibility and simplicity, the brand’s initial collection will be priced from $10-$15 USD. Loved01 will be available starting February 1, 2023 through Loved01.com and at CVS Pharmacy locations nationwide and at CVS.com and launch in select Walmart stores and on Walmart.com in March 2023.

ABOUT JOHN LEGEND
John Legend is an award-winning singer-songwriter, entrepreneur and founder of personal care brand Loved01. Beyond his impressive music career, Legend is an avid advocate for equal opportunity for all people. Legend works to amplify minorities’ voices and representation in spaces they may not be otherwise represented, including the entertainment, beauty and personal care industries. Targeting unmet needs in the skincare industry, Legend became an early investor in Tristan Walker’s brand BEVEL, the first and only head-to-toe grooming brand for Black men. Continuing his work to amplify minority voices, Legend composed the score for Simone Biles’ SK-II skincare episode of the brand’s animated ‘VS Series’ highlighting Olympic athletes’ real-life challenges and animosity they face due to societal beauty standards and social media. Legend also continues to raise awareness and improve accessibility for the BIPOC community through his efforts as the founder of HUMANLEVEL, an initiative to uplift communities disproportionately impacted by institutionalized racism.

ABOUT A-FRAME
A-Frame is a Los Angeles based holding company that develops talent led, personal care and wellness brands created to solve everyday problems for those that need it most. At A-Frame, authentic representation and care is fully embodied by a team that genuinely reflects, at all levels, the communities being served.

SOURCE Loved01

   

health and wellness

Investigators Explore Impact of Cigarette Smoking and Alcohol Consumption on Black Breast Cancer Survivors

Published

on

Rutgers Cancer Institute of New Jersey Results Published in JAMA Network Open

Newswise — New Brunswick, N.J. – Investigators from Rutgers Cancer Institute of New Jersey, the state’s  only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas Health, found that a higher risk of mortality in Black breast cancer survivors is associated with a history of cigarette smoking along with regular alcohol consumption at the time of diagnosis. The work, led by Nur Zeinomar, PhD, MPH, associate member of the Cancer Prevention and Control Program at Rutgers Cancer Institute, along with senior author Elisa V. Bandera, MD, PhD of Rutgers Cancer Institute, Rutgers School of Public Health  and Rutgers Robert Wood Johnson Medical School,is published in JAMA Network Open (doi:10.1001/jamanetworkopen.2022.52371)

There is limited data about how lifestyle factors are associated with breast cancer prognosis in Black women, as the majority of evidence is based on studies in white breast cancer survivors.

Maintaining a healthy lifestyle, which includes limited alcohol consumption and avoiding smoking, has been associated with improved survival following a breast cancer diagnosis (Li Q et al. Breast Cancer. 2022 Nov;29(6):957-966.). In this population-based cohort study of 1,926 Black breast cancer survivors, researchers found that those who smoked at the time of breast cancer diagnosis had a 52 percent increased risk for death due to any cause, compared with those who never smoked. This association was most pronounced for women with greater ‘pack-years’ of smoking and who regularly consumed alcohol, suggesting that smoking at the time of diagnosis is associated with a higher risk of mortality among Black breast cancer survivors, report the authors.

“Our findings add to the evidence of the detrimental health impacts of smoking and underscore the need of tailored and targeted survivorship care for breast cancer survivors, particularly Black women and those with heavier levels of smoking,” notes Dr. Zeinomar, who is also an assistant professor of medicine at Rutgers Robert Wood Jonson Medical School. “According to the American Cancer Society, there is a 40 percent increased risk of death for Black women diagnosed with breast cancer compared to non-Hispanic white women, thus better understanding how these modifiable risk factors are associated with prognosis is important for clinical recommendations and management following a breast cancer diagnosis.”

The authors note limitations of the study include limited information on cigarette smoking and alcohol consumption after diagnosis, as well as data on other types of smoking including passive smoking and e-cigarette use. Additionally, both alcohol consumption and smoking could potentially be underreported as both exposures in the study were based on self-reporting. The investigators say future studies should examine the role of continued smoking after a cancer diagnosis as well as smoking cessation in breast cancer survivorship.

Author acknowledgements, disclosures and other information can be found here 

About Rutgers Cancer Institute of New Jersey  As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support Rutgers Cancer Institute, call 848-932-8013 or visit www.cinj.org/giving

Advertisement

Source: Rutgers Cancer Institute of New Jersey

Continue Reading

fitness

POLAR AND MOSSY OAK INTRODUCE A NEW LINE OF THE POLAR GRIT X PRO FOR OUTDOOR, SPORTS ENTHUSIASTS

Published

on

Polar and Mossy Oak team up to offer the ultimate training, outdoor multisport watch in iconic camouflage patterns

BETHPAGE, N.Y., Jan. 30, 2023 /PRNewswire/ — Polar Electro (www.polar.com), the world leader in personal guidance for fitness, sport, and health, and Mossy Oak (www. mossyoak.com), the leading branded camouflage and outdoor lifestyle company, have announced their collaboration on the Polar Grit X Pro, a premium outdoor multisport watch that is engineered for extreme durability and equipped with superior navigation and training tools. Perfect for outdoor and camping enthusiasts, this premier partnership unites one of the toughest, lightest, and most versatile Polar watches with the iconic look of Mossy Oak camouflage patterns, available in Country DNA and Bottomland.

Polar Grit X Pro

“We are excited to join forces with a household name like Mossy Oak that exemplifies loyalty to the outdoors and their customers,” says Michael Valentino, Senior Director of Consumer & B2B Sales of Polar US. “Now, nature lovers will be able to enjoy the functionality of the Polar Grit X Pro, offering unrivaled training and navigation tools, ultra-long battery life, and durability, matched with classic camouflage patterns that our customers can sport on a camping trip or hiking trail”, he adds.

Polar Grit X Pro features include:

  • Scratch-resistant sapphire glass lens
  • Stainless-steel bezel
  • Military-grade durability
  • Water Resistant Up to 100m (about the height of the Statue of Liberty)
  • Up to 7 days of battery on a single charge
  • Advanced wrist-based heart rate tracking with Polar Precision Prime™
  • Route planning and turn-by-turn guidance powered by komoot
  • Route and elevation profiles
  • Always-on outdoor dashboards, including altimeter, compass, coordinates, weather, and daylight times
  • Automatic sleep tracking and recovery apps

The Mossy Oak enterprise extends across nearly all aspects of the outdoors lifestyle aiming to help people in connecting with the wilderness. Over the years, Mossy Oak has carved a path in the outdoor apparel and gear space through its iconic camouflage patterns that are continuously voted a number one camouflage print in America, now featured in the Polar Grit X Pro.

“Our partnership with Polar was the perfect opportunity to expand our footprint with consumers who not only love exploring the outdoors but also taking care of their health with a deep understanding of wellness and technology,” says Chris Paradise, Senior Vice President Chief Sales Officer, Mossy Oak. “Featuring patterns like Bottomland that launched our brand with Country DNA that highlights the evolution of our versatile prints, really shows how far Mossy Oak has come over the years to now being paired with science-backed technology for the adventurous outdoor lover”, he continues.

The Polar Grit X Pro is priced at $529.95, and will be available in Mossy Oak patterns on January 30, 2023 in major retail stores, as well as online at Polar.com.

ABOUT POLAR

Advertisement

For over 45 years, Polar has provided guidance for health, sports, and fitness with the world’s best measurement technology and data-driven user insight to help people – from first timers to professional athletes – succeed in their pursuit of a happier and healthier life. Renowned for an unparalleled dedication to science and deep understanding of sports, wellness, and technology, Polar has cemented itself globally within the industry as the go-to partner for anyone looking to discover their true potential. Our award-winning product range includes pioneering sports wearables that work elegantly with Polar training apps and cloud services.

For more information, please visit Polar.com.
Follow Polar on FacebookInstagramTikTokLinkedIn,  and YouTube.

ABOUT MOSSY OAK

Established in 1986, Haas Outdoors Inc. is headquartered in West Point, Miss., and is home to Mossy Oak. For more than 35 years, Mossy Oak has been a leading outdoor lifestyle brand specializing in developing and marketing modern camouflage designs for hunters and outdoors enthusiasts and helping people get closer to nature. The Mossy Oak Brand and patterns can be found on a multitude of products worldwide. Haas Outdoors Inc. is the parent company of Mossy OakBioLogicCapture ProductionsMOOSE MediaNativ NurseriesNativ LivingGameKeepersGameKeepers KennelsMossy Oak Properties, and Mossy Oak GO. Mossy Oak is the official camouflage of the National Wild Turkey FederationDucks UnlimitedMack’s Prairie Wings, and Bonefish and Tarpon Trust.

Follow Mossy Oak on FacebookTwitterInstagramPinterest, and YouTube.

SOURCE Polar Electro

Advertisement
Continue Reading

Health

Coordination of COVID-19 Vaccine Clinical Trials Produces a ‘Treasure Trove’ of Data and a Model for the Future

Published

on

Harmonized approach and vast database of trial participants could bolster future research well beyond SARS-CoV-2

Newswise — SEATTLE – The federally funded COVID-19 Prevention Network (CoVPN), headquartered at Fred Hutchinson Cancer Center in Seattle, was instrumental in the rapid development of safe, effective and lifesaving COVID-19 vaccines during earlier phases of the pandemic.

Its vital work to expedite Phase 3 COVID-19 vaccine clinical trials also resulted in a highly collaborative and harmonized approach that can serve as a national and even international model for major research initiatives while also guiding responses to future public health emergencies.

That’s the overarching theme from a new study published Monday, Jan. 23, in JAMA Network Open.

“Our success, which depended entirely on the investments into HIV vaccine research, can be replicated for other important research initiatives and highlights the importance of investments that boost pandemic preparedness for years to come,” explained James G. Kublin, MD, MPH, executive director of CoVPN and senior and corresponding author of the study.

Additionally, he and his colleagues, including  Alfredo Mena Lora, MD, assistant professor of medicine at the University of Illinois at Chicago, and co-first author Jessica Long, PhD, MPH, a postdoctoral fellow at the University of Washington Department of Medicine in Seattle, noted that the COVID-19 clinical trials produced a vast database of critical information that could help researchers answer pressing questions about this novel virus moving forward. 

“The harmonization of data across trials is a new strategy that will set the standard for collaboration in future clinical trials,” said Mena Lora. 

Advertisement

The authors detail how CoVPN was able to help secure authorized vaccines in less than a year by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health as part of Operation Warp Speed. Its mission was, and continues to be, to support the rapid development of vaccines for the U.S. and global populations by coordinating and implementing Phase 3 trials for COVID-19 vaccine candidates.

CoVPN officials were able to leverage existing resources, including clinical and laboratory infrastructure, community partnerships and research expertise, to get clinical sites to quickly pivot to conduct the vaccine trials as soon as investigational products were ready for Phase 3 testing.

“The CoVPN approach drew on years of experience and infrastructure from partnering networks and institutions, which not only allowed for rapid rollout of the trials, but also contributed to broader representation of trial participants,” said Long.

Overall, CoVPN deployed five Phase 3 clinical trials involving more than 136,000 participants to test the safety and effectiveness of COVID-19 vaccines. While doing so, it implemented several innovative procedures that were essential to its ultimate success. These included:

  • Harmonized study designs that were similar in relative size, number of endpoints and time to analysis.
  • A model that accelerated vaccine development by allowing phases to occur in parallel rather than sequentially. For example, vaccine manufacturing and scale-up were greenlighted while the trials were ongoing in anticipation of meeting efficacy targets.
  • Establishment of a single Data Safety Monitoring Board for review and oversight of all vaccine studies.
  • Targeted outreach and enrollment efforts supported by an online screening registry to ensure broad and diverse representation among study participants. Extensive engagement was conducted with communities and community leaders to build and enhance trust in the science to help enroll more Black, Indigenous and people of color (BIPOC) volunteers who are historically underrepresented in clinical trials.
  • A cross-platform approach that led to harmonization of data collection across trials and the ability to analyze data from all studies.

“This unique, cross-platform concept allowed for sharing of data from all of the studies and helped bridge gaps in understanding so we could better answer key research questions and guide policy decisions,” explained Kublin, who’s also a principal staff scientist at Fred Hutch. 

Larry Corey, MD, an internationally renowned expert in vaccine development, and principal co-investigator of CoVPN, believes the success of COVID-19 clinical trials should be thought of as an important model for developing vaccines for significant infectious diseases globally.

“Harmonizing study design, enrollment, clinical endpoints and methods for follow-up could very well become best practices that shape the future landscape of major research initiatives and pandemic responses,” he said. 

Advertisement

Kublin and colleagues regard the vast database from more than 130,000 trial participants, including over 2,500 with documented COVID-19 cases, as a “treasure trove” of data that could help unlock mysteries about the virus. For example, they noted that the pooled data from five trials can help address specific questions such as:

  • How effective are vaccines for at-risk groups?
  • Can vaccines have an impact on long COVID?
  • Are safety, immunogenicity and vaccine efficacy different in special populations, such as people living with HIV?
  • What impact do chronic health conditions have on vaccine efficacy or protection duration?
  • What are the impacts of variants on both the population at large and within special communities?

Additional CoVPN publications planned for the months ahead will address many of these topics. Researchers who have ideas for further investigation and want to collaborate with CoVPN can find more information here.

Source: Covid-19 Prevention Network (CoVPN)

Continue Reading

Subscribe to the SPR Newsletter

DON’T MISS A DINK

Be the first to know when the latest episode of Sleeve's Senior Pickleball Report is released on YouTube and more...

We don’t spam! Read our privacy policy for more info.

Advertisement pet, pets, dog, dogs, supplements, Pawlife, Pawlife Pets, dog health, dog treats, all natural, wellness product, dog supplements, all-natural
Advertisement

Want more stories 👋
News you Can Use, "THIS MOMENT!"

Sign up to receive awesome articles directly to your inbox, every month.

We don’t spam! Read our privacy policy for more info.

Advertisement

The Latest from TNC Network: TNC Network News

Trending

%d bloggers like this: